# Sunitinib for Advanced Thymus Cancer Following Earlier Treatment

> **NCT01621568** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Thymoma
- Thymus Neoplasms

## Interventions

- **DRUG:** Sunitinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01621568
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-15
- **Primary completion:** 2021-04-30
- **Final completion:** 2024-07-31
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01621568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01621568, "Sunitinib for Advanced Thymus Cancer Following Earlier Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01621568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*